Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | AGXT | P21549 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13543222 | 0.84 | CYP24A1 (0.57) | MTNR1AMTNR1B | |
| SCHEMBL18751676 | 0.84 | CYP1A2 (0.46) | CTBP2CYP1A2POLB | |
| SCHEMBL4071390 | 0.82 | CTBP2 (0.64) | CTBP2CYP1A2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL13543196 | 0.82 | CYP24A1 (0.50) | ALDH1A1POLBMEN1KMT2ASIGMAR1 | |
| SCHEMBL23692350 | 0.81 | SRC (0.45) | CTBP2ALDH1A1HTTMMP13 | |
| SCHEMBL13012127 | 0.81 | PPARA (0.57) | SMN1; SMN2 | |
| SCHEMBL29824310 | 0.81 | PTGS1 (0.67) | CTBP2CYP1A2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL229067 | 0.81 | PTGS1 (0.67) | CTBP2CYP1A2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL269177 | 0.81 | CTBP2 (0.62) | CTBP2CYP1A2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL15513856 | 0.81 | CTBP2 (0.62) | CTBP2CYP1A2ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158022-A1 | METHODS OF USING MYT1 INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2023-05-25 | — | — | US | disclosed |
| US-9856265-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-02 | — | — | US | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| US-9623022-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-18 | — | — | US | disclosed |
| US-9353103-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-31 | — | — | US | disclosed |
| US-20150218153-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN R & D IRELAND (IE) | 2015-08-06 | — | — | US | disclosed |
| US-9040562-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2015-05-26 | — | — | US | disclosed |
| US-20140255347-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN R&D IRELAND (IE) | 2014-09-11 | — | — | US | disclosed |
| US-8754106-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-06-17 | — | — | US | disclosed |
| US-8741926-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-06-03 | — | — | US | disclosed |
| US-7879885-B2 | such as N-(2-Amino-6-methylpyridin-3-ylmethyl)-N-{2-[2-[(2-amino-6-methyl-pyridin-3-ylmethyl)formylamino]-1-(2-hydroxyethyl)-propenyldisulfanyl]-4-hydroxy-1-methylbut-1-enyl}formamide, used for inhibiting cell proliferation and tumor cell growth, stimulating apoptosis in tumor cells and treating cancer | ARRAY BIOPHARMA, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090203663-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | US | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ASTRAZENECA AB | 2009-04-30 | — | — | US | disclosed |
| US-20070293501-A1 | Thioalkeneamides as Transketolase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293501-A1 | Thioalkeneamides as Transketolase Inhibitors | ARRAY BIOPHARMA INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-6867310-B1 | Arylation and vinylation of activated carbons | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | CTBP2 3929/4885CYP1A2 41/4885ALDH1A1 2683/4885 |
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | TKT, RRM2, TYMS | CTBP2 3818/4885CYP1A2 2572/4885ALDH1A1 766/4885 |
| US-20100317621-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | CTBP2 3407/4885CYP1A2 740/4885ALDH1A1 430/4885 |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | IL1R1, IDO1, TLR1 | CTBP2 4378/4885CYP1A2 62/4885ALDH1A1 93/4885 |
| US-20140255347-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | CTBP2 3929/4885CYP1A2 41/4885ALDH1A1 2683/4885 |
| US-20090203663-A1 | CHEMICAL COMPOUNDS | ITGB5, ITGB1, ITGA2B | CTBP2 1349/4885CYP1A2 4462/4885ALDH1A1 565/4885 |
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ITGA2B, ITGB1, ITGB5 | CTBP2 3475/4885CYP1A2 4447/4885ALDH1A1 372/4885 |
| US-20230158022-A1 | METHODS OF USING MYT1 INHIBITORS | MYT1, MNAT1, MYLK3 | CTBP2 2007/4885CYP1A2 3815/4885ALDH1A1 4237/4885 |
| US-20070293501-A1 | Thioalkeneamides as Transketolase Inhibitors | TKT, AKR1A1, RRM2 | CTBP2 4232/4885CYP1A2 1396/4885ALDH1A1 132/4885 |
| US-20150218153-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, CYP3A7, HCCS | CTBP2 3929/4885CYP1A2 41/4885ALDH1A1 2683/4885 |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ITGB5, ITGB1, ITGA2B | CTBP2 2899/4885CYP1A2 4569/4885ALDH1A1 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.